Skip to main content

Advertisement

Table 1 Patient disposition in the axitinib and placebo titration arms

From: Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study

Disposition, n (%) Axitinib Titration n = 56 Placebo Titration n = 56
Discontinued treatment 47 (84) 55 (98)
 Disease progression/relapse 35 (63) 40 (71)
 Adverse event 8 (14) 5 (9)
 Death 2 (4) 1 (2)
 Refusal of treatment for reason other than adverse event 1 (2) 4 (7)
 Global deterioration in health status 1 (2) 1 (2)
 Protocol violation 0 1 (2)
 Other 0 3 (5)
Remaining on treatment 9 (16) 1 (2)